Osseointegration Failure of Dental Implant Due to Infection Clinical Trial
Official title:
Inflammation and Microbiology Pattern on Two-piece Zirconia Dental Implant Compared to Titanium Dental Implants. Randomized Clinical Control Trial
2 Arms (60 subjects - 30 each arm). Experimental group with two-pice zirconia dental implant and Control group with two-piece titanium dental implant Evaluate Changes in inflammatory and microbiology levels from T0 (baseline) T2 (8 weeks) and T3 (after crown placement) Also evaluate secondary outcomes: marginal bone loss (MBL), gingival height (GH) levels, osseointegration, gender, age, time of surgery, anatomical position and implant stability. p values<0.05 were considered statistically significant
| Status | Not yet recruiting |
| Enrollment | 60 |
| Est. completion date | January 1, 2019 |
| Est. primary completion date | August 1, 2018 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: Single implants in any area (maxillary and mandibular), extracted teeth for at least 3 months before implant placement, with bone volumes sufficient (at least 2 mm mesial, distal, buccal and palatal) to accommodate dental implant without the need for regeneration. Controlled oral hygiene, absence of any lesions in the oral cavity, at least 2 mm keratinized tissue. In addition, patients must agree to participate in a postoperative control program and signed the informed consent. Exclusion Criteria: 1 - allergic to local anaesthetics, or any of the other components. 2 - Patients with hepatic or renal dysfunction 3 - Patients with epilepsy, shock, cardiac conduction disorders or myasthenia gravis 4 - Patients with myocardial injury 5 - Hyperthyroidism 6 - Severe Hypertension 7 - Insufficient bone volume 8 - Smoking more than five cigarettes / day 9 - Excessive alcohol consumption 10 - localized anti-tumour radiation therapy of the oral cavity 11 - Chemotherapy 12 - Liver Diseases 13 - immunosuppressed patients 14 - Patients taking corticosteroids 15 - Pregnancy 16 - inflammatory and autoimmune diseases of the oral cavity |
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| Instituto de Implantologia |
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Osseointegration | measure if the healing process of bone was successful | from T0 to T2 - 2 month | |
| Primary | Marginal bone loss | measure bone level from T0 baseline to T3 | 4 month after T0 | |
| Primary | IL1b concentration | Measure IL fluid at T0 and T2 for IL1b characterization | 4 month | |
| Primary | IL6 concentration | Measure IL fluid at T0 and T2 for IL1b characterization | 4 month | |
| Primary | Microbiologic samples | Measure crevicular fluid at T0 and T2 for bacteria characterization | 4 month |